【摘要】 目的评价FOLFOX4方案治疗进展期及转移胃癌的疗效与安全性。方法按FOLFOX4方案给药,奥沙利铂85mg/m2,静脉滴注2h,第1d;亚叶酸钙(CF)200mg/m2,静脉滴注2h,第1,2d;5-FU 400mg/m2,于CF滴完后静脉注射10m in,第1,2d;5-FU600mg/m2,持续泵入22h,第1,2d;每2~3周重复。结果入组观察48例,可评价疗效者48例,其中完全有效(CR)6例(12.5%),部分有效(PR)17例(35.4%),稳定(SD)20例(41.7%),进展(PD)5例(10.4%)。总有效率(ORR)47.9%(23/48),初治ORR 64.3%(18/28),复治ORR25.0%(5/20)。中位疾病无进展时间(TTP)5.8个月,中位生存时间9个月。不良反应主要为白细胞减少,消化道不良反应较轻,较明显的不良反应为周围神经毒性,无化疗相关死亡。结论FOLFOX4方案治疗晚期胃癌疗效较高,不良反应轻而且安全。更多还原

【Abstract】 Objective To evaluate the efficiency and toxicity of the chemotherapy regimen FOLFOX4 for the patient with advanced stomach carcinoma.Methods Oxaliplatin 85 mg/m IV over 2 hours,day 1,Leucovorin 400 mg/m IV over 2 hours,days 1 and 2,5-FU 400 mg/m IV bolus,then 600 mg/m IV over 22 hours continuous infusion,days 1 and 2,Repeat every 2 or 3 weeks.Results 48 patients with advanced stomach carcinoma entered the study.Among them 6 patients reached CR,17 patients reached PR,The overall response was 47.9%. The main toxicity was neuron-sensory toxicity.Conclusion FOLFOX4 has better efficiency for advanced stomach carcinoma and its toxicity is tolerable.更多还原